If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today

Core Insights - AbbVie has shown significant growth over the past decade, with an initial investment of $1,000 now worth $3,350, or $4,105 if dividends were reinvested [2] - The company is recognized for its solid dividend payments, with a recent yield of 3.4% and an annual payout increase from $3.59 in 2018 to $6.47 in 2023 [4] - AbbVie has performed comparably to the S&P 500, with an average annual gain of 12.84% versus 12.62%, and a more pronounced advantage when dividends are reinvested [5] Company Overview - AbbVie, spun off from Abbott Laboratories in 2013, is a major global pharmaceutical company with a market value exceeding $330 billion [6] - The company specializes in various therapeutic areas, including immunology, oncology, aesthetics, neuroscience, and eye care [6] - Despite losing patent protection for its blockbuster drug Humira, AbbVie has a promising pipeline, with successful sales of immunosuppressants Skyrizi and Rinvoq [6] Investment Considerations - Current stock levels suggest AbbVie is neither overvalued nor undervalued, with a price-to-sales ratio of 5.9, slightly above its five-year average of 4.7 [7] - Long-term investors may find the current valuation acceptable, with potential for future appreciation [7]